Antileukotrienes in asthma: present situation

Expert Opinion on Pharmacotherapy
L García-Marcos, A Schuster

Abstract

Leukotrienes are key mediators in asthma. Over the last 5 years, several antileukotrienes, including three receptor antagonists (montelukast, pranlukast and zafirlukast) and one 5-lipoxygenase inhibitor (zileuton), have been marketed and, to date, this class of drugs is being used widely. Still, their definite place in the asthma treatment algorithm is not yet established. These novel drugs have not yet all been evaluated in the same depth, but they have all been shown to possess anti-inflammatory properties and to be effective in chronic asthma treatment. Zafirlukast and montelukast are particularly efficacious in exercise-induced asthma and zileuton appears valuable for treating aspirin-intolerant asthmatics. Clinical comparisons to other anti-asthma drugs are still sparse. The corticosteroid-sparing effect of antileukotrienes is fairly well established except for zileuton, even though this drug has been evaluated most thoroughly in terms of its anti-inflammatory effects. Montelukast is the antileukotriene most extensively evaluated in children and zafirlukast has recently been approved for use in children in the USA, although not yet in Europe. Therapeutic regimes are quite variable depending on the drug, but all of the anti...Continue Reading

References

May 1, 1992·The Journal of Allergy and Clinical Immunology·S R FindlayM Glass
Oct 1, 1987·The American Review of Respiratory Disease·J M Drazen, K F Austen
Oct 1, 1995·American Journal of Respiratory and Critical Care Medicine·A R FischerE Israel
Sep 1, 1995·American Journal of Respiratory and Critical Care Medicine·S E WenzelJ Y Westcott
Dec 1, 1993·Annals of Internal Medicine·E IsraelJ M Drazen
Dec 1, 1993·The American Review of Respiratory Disease·E IsraelJ M Drazen
Mar 1, 1996·American Journal of Respiratory and Critical Care Medicine·S S MeltzerE R Bleecker
Jan 1, 1996·European Journal of Clinical Pharmacology·D R BrocksM J Dennis
Aug 1, 1996·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·W W Busse
Jan 1, 1997·Clinical Pharmacology and Therapeutics·I De LepeleireM Decramer
Apr 1, 1997·American Journal of Respiratory and Critical Care Medicine·Z DiamantP J Sterk
Jan 1, 1997·European Journal of Clinical Pharmacology·W M AwniL M Dube
May 1, 1997·Journal of Clinical Pharmacology·W M AwniJ H Cavanaugh
May 1, 1997·Journal of Clinical Pharmacology·W M AwniC E Halstenson
Jan 1, 1997·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·J GrossmanD Tinkelman
Sep 26, 1997·International Archives of Allergy and Immunology·R OosakiM Kobayashi
Dec 31, 1997·American Journal of Respiratory and Critical Care Medicine·S C LazarusM C Minkwitz
Feb 18, 1998·JAMA : the Journal of the American Medical Association·M E WechslerJ M Drazen

❮ Previous
Next ❯

Citations

Jan 27, 2007·Clinical Rheumatology·R CuchacovichL R Espinoza
Aug 2, 2003·International Immunopharmacology·Umran Soyoğul GürerAdile Cevikbaş
Jan 16, 2002·Current Opinion in Rheumatology·W L Gross
Dec 24, 2005·Allergologia et immunopathologia·J A Castro-RodríguezUNKNOWN Spanish Pediatric Asthma Study Group
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Rafael Stelmach, Alberto Cukier
Jul 5, 2016·Pharmacology & Therapeutics·Linda SwedinMatthew C Catley
Aug 1, 2002·Drugs·Robert W Gotshall

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.